NASDAQ: XFORX4 Pharmaceuticals Inc Stock
$4.13+0.14 (+3.51%)
Updated Mar 31, 2026
XFOR Price
$4.13
Fair Value Price
$2.66
Market Cap
$375.50M
52 Week Low
$1.35
52 Week High
$6.96
P/E
-2.21x
P/B
2.02x
P/S
4.82x
PEG
N/A
Dividend Yield
N/A
Revenue
$35.11M
Earnings
-$79.20M
Gross Margin
83.6%
Operating Margin
-200.16%
Profit Margin
-225.6%
Debt to Equity
0.56
Operating Cash Flow
-$86M
Beta
1.27
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
XFOR Overview
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine XFOR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
XFOR
Ranked#223 of 463
Ranked#223 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $16.64 | A | |
| $23.30 | A | |
| $14.82 | A |
Be the first to know about important XFOR news, forecast changes, insider trades & much more!
XFOR News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how XFOR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XFOR ($4.13) is overvalued by 55% relative to our estimate of its Fair Value price of $2.66 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
XFOR ($4.13) is not significantly undervalued (55%) relative to our estimate of its Fair Value price of $2.66 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
XFOR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more XFOR due diligence checks available for Premium users.
Valuation
XFOR fair value
Fair Value of XFOR stock based on Discounted Cash Flow (DCF)
Price
$4.13
Fair Value
$2.66
Overvalued by
55.00%
XFOR ($4.13) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
XFOR ($4.13) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
XFOR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
XFOR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.21x
Industry
26.93x
Market
30.95x
XFOR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.02x
Industry
4.73x
XFOR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
XFOR's financial health
Profit margin
Revenue
$2.6M
Net Income
-$23.9M
Profit Margin
-931.7%
XFOR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
XFOR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$290.5M
Liabilities
$104.2M
Debt to equity
0.56
XFOR's short-term assets ($261.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XFOR's short-term assets ($261.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XFOR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
XFOR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$15.5M
Investing
$16.8M
Financing
$146.1M
XFOR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XFOR vs Biotech Stocks
X4 Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.